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Introduction: Patients with acute myocardial infarction (AMI) have a greatly increased risk of 
subsequent cardiovascular event even if after successful revascularization therapy was performed. 
Pharmacotherapy for secondary prevention is mandatory in this clinical setting. The Survival and 
Ventricular Enlargement (SAVE) trial was large randomized, double-blind, placebo-controlled trial 
in 2231 patients within 3 to 16 days after AMI and left ventricular ejection fraction of 40 percent or 
less but without overt heart failure or symptoms of myocardial ischemia. In this trial, mortality from 
all causes was significantly reduced in an angiotensin-converting enzyme inhibitor (ACE-I) group as 
compared with the placebo group (Pfeffer et al, 1992). Japanese Circulation Society guidelines for 
secondary prevention for myocardial infarction also recommend Angiotensin II receptor blocker 
(ARB) is an alternative approach to renin-angiotensin-aldosterone system inhibition. Recent trials 
have demonstrated that ARBs are as effective as ACE-Is in improving survival and reducing 
cardiovascular morbidity in patients with congestive heart failure. Preclinical data demonstrate that 
RAS activation plays an important role in atherosclerosis and that renin-angiotensin-aldosterone 
system (RAS) inhibition may have a direct beneficial effect on the arterial wall (Ferrario and Strawn, 
2006; Yusuf et al, 2000). Our hypothesis is that the combined effects of these drugs might have 
higher anti-atherosclerotic efficacy. We assessed the effects of the ARB on coronary plaque 
progression in patients of AMI after successful coronary revascularization who received an ACE-I.  
 
Methods: After local ethics committee approval and obtaining informed concent, 116 patients with 
AMI were randomly assigned to receive a combination of valsartan and captopril or captopril alone. 
Non-culprit intermediate coronary atherosclerosis was assessed by intravascular ultrasound. The 
primary and secondary end points were the nominal change in percent atheroma volume (PAV) and 
the percent changes in lumen volume (%ΔLV), respectively. The target lesion was measured at 
1-mm intervals. The luminal/intimal borders were traced manually to determine the lumen 
cross-sectional area (CSA). The external elastic membrane (EEM) CSA, which represents the area 
encompassed by the medial/adventitial border, was measured by tracing the leading edge of the 
adventitia. Atheroma volume (AV) was calculated as the sum of the differences between the EEM 
and lumen CSAs across all evaluable slices: atheroma volume = Σ (EEM CSA – lumen CSA). 
Percent atheroma volume (PAV) was calculated as AV/Σ EEM CSA × 100. The primary end point, 
the nominal change in PAV, was calculated with the following formula: PAV (follow-up) – PAV 
(baseline). The secondary endpoint, the percent change in lumen volume (%ΔLV), was calculated 
with the following formula: (follow-up lumen volume – baseline lumen volume)/baseline lumen 
volume × 100. 
 
Results: The combination group showed a significant lower systolic blood pressure (117 vs. 125 mm 
Hg; p = 0.02) and a lower plasma aldosterone level (56 vs. 75 pg/ml; p = 0.02) at follow-up. The 
nominal change in PAV was slightly lower in the combination group than in the ACE-I group (-1.9 
vs. -0.68%, p = 0.06). %ΔLV was -0.3% in the ACE-I group and was 4.3% in the combination 
group (p = 0.03). Logistic regression analysis showed that additional ARB therapy was 
independently associated with lumen volume enlargement (odds ratio 2.144; 95% confidence 
interval, 1.818 to 5.618; p = 0.03).  
 
Discussion: In this study of patients with AMI, additional ARB therapy had minimal impact on the 
progression of coronary atherosclerosis as compared with an ACE-I alone. The absence of a decrease 
in plaque in the combination group as compared with the ACE-I group in our study is in accordance 
with the results of these pivotal clinical trials, although whether coronary plaque progression is 
directly related to outcomes remains to be determined. RAS inhibition with an ACE-I alone may be 
sufficient and dual blockade might not confer any additional benefits in terms of reducing the 
progression of coronary atherosclerosis in patients with AMI. However, we cannot exclude the 
possibility that ARB induced a change in the histologic composition of plaque, which was not 
assessed in this study. Further study must be required to evaluate the impact of RAS inhibition in 
human coronary atherosclerosis. 
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